Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool June 30, 2010 Brian Orelli	Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term.
The Motley Fool November 26, 2008 Brian Orelli	Abraxis Fires AstraZeneca, Gets Fired Up Buoyed by deep pockets filled with cash after it separated from its generic drug business, Abraxis Bioscience is moving into the deep end with the big boys.
The Motley Fool August 13, 2007 Brian Orelli	Little Drug, Big Sales Huge increases in revenue usually drive stock prices upward, but Abraxis BioScience's stock has fallen 15% from its high last week, despite releasing a stellar earnings report.
The Motley Fool November 17, 2008 Brian Orelli	The Little Chemotherapy That Could Abraxis BioScience has a lot of potential, but, in this market, the company is going to have to show investors that it can make it over the hill before they're going to jump on board.
The Motley Fool April 2, 2008 Brian Orelli	Abraxis Tardy, but With a Note Abraxis Bioscience finally gets around to releasing fourth-quarter 2007 financials.
The Motley Fool May 14, 2007 Brian Orelli	Little Product, Big Profits Abraxis Bioscience reports increased sales of its nano-sized drug. Investors, take note.
The Motley Fool March 30, 2011 Brian Orelli	Amgen's Long Shot Comes Up Short Amgen and Takeda Pharmaceutical's motesanib didn't extend overall survival in lung cancer patients when combined with Bristol-Myers Squibb's Taxol and carboplatin.
The Motley Fool July 6, 2007 Brian Orelli	Breaking Up Is Easy to Do Drugmaker Abraxis splits in two. It will be a few years before investors know whether the breakup was beneficial to the new companies.
The Motley Fool January 11, 2011 Brian Orelli	An Undeserved Kick in the Pants Celgene gets knocked around.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
The Motley Fool September 12, 2007 Brian Orelli	Fitting Fission at Abraxis BioScience Abraxis BioScience will split itself into a biotech firm and a generic drug business. Both new companies stand to benefit, but will investors?
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
The Motley Fool June 2, 2008 Brian Orelli	Valuing One-Drug Wonders With only one drug on the market, these pharmas lack positive earnings.
The Motley Fool November 7, 2006 Brian Lawler	Abraxis Advances The drug developer's platform technology could improve existing drugs, much to investors' excitement.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
BusinessWeek April 11, 2005 Arlene Weintraub	A Nano Drug's Giant Promise After seeking FDA approval for a decade, American Pharmaceutical Partners' Abraxane, which offers a less-toxic cancer treatment, has doctors and investors hopeful.
The Motley Fool July 28, 2006 Jack Uldrich	Tiny Particles Cause a Big Storm for Abraxis Elan sues Abraxis Bioscience for patent infringement. Abraxis' stock, which has fallen nearly 60% from its 52-week high, might make a compelling buy for more risk-tolerant investors.
The Motley Fool November 24, 2009 Brian Orelli	4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc.
The Motley Fool May 15, 2007 Mike Havrilla	On the Threshold at Sonus The pharma is testing one drug that could be used to treat several types of cancer. Investors, take note.
The Motley Fool November 24, 2008 Brian Orelli	Bristol Rolls Snake Eyes in Europe European officials reject Bristol-Myers Squibb's breast cancer treatment, Ixempra.
The Motley Fool April 8, 2008 Brian Orelli	Songs of the One-Drug Wonders Will these companies become big-name drugmakers or get lost in history? Let's take a quick look at: Abraxis Bioscience... Elan... Amylin Pharmaceuticals... Onyx Pharmaceuticals...
The Motley Fool November 12, 2007 Brian Orelli	Valuing a Breakup Abraxis makes its final earnings report before it becomes two companies. Its hospital-based products division will hereafter be known as APP Pharmaceuticals.
The Motley Fool September 25, 2007 Brian Orelli	No Drugs, No Rally Sonus Pharmaceuticals' lead drug fails in phase 3 trials, so the stock crashes.
The Motley Fool November 21, 2008 Brian Orelli	The Comeback of the Century? AstraZeneca is trying to revive Iressa.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool April 28, 2011 Brian Orelli	Celgene Gets No Love The market shrugs off a solid quarter.
The Motley Fool March 26, 2008 Brian Lawler	Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population.
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
The Motley Fool October 6, 2010 Brian Orelli	Celgene Is All Grown Up An acquirer is on the prowl.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool December 8, 2009 Brian Orelli	Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
The Motley Fool October 30, 2006 Brian Lawler	Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool May 24, 2010 Brian Orelli	ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
BusinessWeek January 30, 2006 Catherine Arnst	Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool April 1, 2009 Brian Orelli	Conservative Celgene's Conundrum The drugmaker said it expected to make the low end of its previous guidance ranges for non-GAAP revenue and earnings per share for the year. It's not bad news, but it hurt the company nonetheless.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
The Motley Fool January 18, 2005 Wherrett & Yelovich	A Giant Leap for Nano American Pharmaceutical gains approval of a breakthrough drug. Its stock soars on the news.
BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
The Motley Fool January 29, 2010 Brian Orelli	Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.